{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéogénomique : Questions médicales les plus fréquentes",
"headline": "Protéogénomique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéogénomique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-01",
"dateModified": "2025-03-28",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéogénomique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéomique",
"url": "https://questionsmedicales.fr/mesh/D040901",
"about": {
"@type": "MedicalCondition",
"name": "Protéomique",
"code": {
"@type": "MedicalCode",
"code": "D040901",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "H01.181.122.738"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Protéogénomique",
"alternateName": "Proteogenomics",
"code": {
"@type": "MedicalCode",
"code": "D000071696",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Bing Zhang",
"url": "https://questionsmedicales.fr/author/Bing%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: bing.zhang@bcm.edu."
}
},
{
"@type": "Person",
"name": "Pei Wang",
"url": "https://questionsmedicales.fr/author/Pei%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics and Genomic Sciences, Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA."
}
},
{
"@type": "Person",
"name": "Li Ding",
"url": "https://questionsmedicales.fr/author/Li%20Ding",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine and Genetics, Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO 63110, USA; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO 63108, USA. Electronic address: lding@wustl.edu."
}
},
{
"@type": "Person",
"name": "Bo Wen",
"url": "https://questionsmedicales.fr/author/Bo%20Wen",
"affiliation": {
"@type": "Organization",
"name": "Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA."
}
},
{
"@type": "Person",
"name": "Ana I Robles",
"url": "https://questionsmedicales.fr/author/Ana%20I%20Robles",
"affiliation": {
"@type": "Organization",
"name": "Office of Cancer Clinical Proteomics Research, National Cancer Institute, Bethesda, MD 20892, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A Clinical Diagnostic Value Analysis of Serum CA125, CA199, and HE4 in Women with Early Ovarian Cancer: Systematic Review and Meta-Analysis.",
"datePublished": "2022-05-25",
"url": "https://questionsmedicales.fr/article/35664644",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/9339325"
}
},
{
"@type": "ScholarlyArticle",
"name": "Viewing early life without labels: optical approaches for imaging the early embryo.",
"datePublished": "2024-04-22",
"url": "https://questionsmedicales.fr/article/38647415",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1093/biolre/ioae062"
}
},
{
"@type": "ScholarlyArticle",
"name": "BMI increase during early childhood in boys with cystic fibrosis and early adrenarche.",
"datePublished": "2024-01-25",
"url": "https://questionsmedicales.fr/article/38270329",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ppul.26861"
}
},
{
"@type": "ScholarlyArticle",
"name": "Promoting early childhood oral health and preventing early childhood caries on Instagram.",
"datePublished": "2023-01-05",
"url": "https://questionsmedicales.fr/article/36686599",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/froh.2022.1062421"
}
},
{
"@type": "ScholarlyArticle",
"name": "Machine learning-derived peripheral blood transcriptomic biomarkers for early lung cancer diagnosis: Unveiling tumor-immune interaction mechanisms.",
"datePublished": "2024-10-16",
"url": "https://questionsmedicales.fr/article/39415336",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/biof.2129"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Disciplines des sciences naturelles",
"item": "https://questionsmedicales.fr/mesh/D010811"
},
{
"@type": "ListItem",
"position": 3,
"name": "Chimie",
"item": "https://questionsmedicales.fr/mesh/D002621"
},
{
"@type": "ListItem",
"position": 4,
"name": "Biochimie",
"item": "https://questionsmedicales.fr/mesh/D001671"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéomique",
"item": "https://questionsmedicales.fr/mesh/D040901"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéogénomique",
"item": "https://questionsmedicales.fr/mesh/D000071696"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéogénomique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéogénomique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéogénomique",
"description": "Comment la protéogénomique aide-t-elle au diagnostic des maladies ?\nQuels tests sont utilisés en protéogénomique ?\nLa protéogénomique peut-elle détecter des cancers ?\nQuels échantillons sont analysés en protéogénomique ?\nLa protéogénomique est-elle utilisée en médecine personnalisée ?",
"url": "https://questionsmedicales.fr/mesh/D000071696?mesh_terms=Early+Detection+of+Cancer&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéogénomique",
"description": "Quels symptômes peuvent être liés à des anomalies protéiques ?\nLes maladies auto-immunes sont-elles étudiées en protéogénomique ?\nComment les protéines affectent-elles les symptômes ?\nLes symptômes de maladies métaboliques sont-ils liés à la protéogénomique ?\nPeut-on prédire des symptômes grâce à la protéogénomique ?",
"url": "https://questionsmedicales.fr/mesh/D000071696?mesh_terms=Early+Detection+of+Cancer&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéogénomique",
"description": "La protéogénomique peut-elle aider à la prévention des maladies ?\nQuels facteurs de risque sont identifiés par la protéogénomique ?\nComment la protéogénomique influence-t-elle les programmes de dépistage ?\nPeut-on prévenir des maladies grâce à des interventions protéogénomiques ?\nLa nutrition peut-elle être influencée par la protéogénomique ?",
"url": "https://questionsmedicales.fr/mesh/D000071696?mesh_terms=Early+Detection+of+Cancer&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéogénomique",
"description": "La protéogénomique influence-t-elle les traitements ?\nQuels types de traitements sont développés grâce à la protéogénomique ?\nLa protéogénomique aide-t-elle à la résistance aux médicaments ?\nLes traitements peuvent-ils être personnalisés grâce à la protéogénomique ?\nQuels médicaments sont influencés par la protéogénomique ?",
"url": "https://questionsmedicales.fr/mesh/D000071696?mesh_terms=Early+Detection+of+Cancer&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéogénomique",
"description": "Quelles complications peuvent survenir en cas d'anomalies protéiques ?\nLes maladies cardiovasculaires sont-elles liées à la protéogénomique ?\nComment la protéogénomique aide-t-elle à comprendre les complications ?\nLes complications liées à la protéogénomique sont-elles évitables ?\nPeut-on prédire des complications grâce à la protéogénomique ?",
"url": "https://questionsmedicales.fr/mesh/D000071696?mesh_terms=Early+Detection+of+Cancer&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéogénomique",
"description": "Quels sont les principaux facteurs de risque identifiés par la protéogénomique ?\nLa protéogénomique peut-elle identifier des risques environnementaux ?\nLes habitudes de vie influencent-elles les facteurs de risque protéogénomiques ?\nComment la génétique influence-t-elle les facteurs de risque ?\nPeut-on modifier les facteurs de risque grâce à la protéogénomique ?",
"url": "https://questionsmedicales.fr/mesh/D000071696?mesh_terms=Early+Detection+of+Cancer&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment la protéogénomique aide-t-elle au diagnostic des maladies ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet d'identifier des biomarqueurs protéiques spécifiques pour un diagnostic plus précis."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés en protéogénomique ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques comme la spectrométrie de masse et l'électrophorèse sont couramment utilisées."
}
},
{
"@type": "Question",
"name": "La protéogénomique peut-elle détecter des cancers ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle aide à identifier des protéines spécifiques associées à différents types de cancers."
}
},
{
"@type": "Question",
"name": "Quels échantillons sont analysés en protéogénomique ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des échantillons de tissus, de sang ou de fluides biologiques sont souvent analysés."
}
},
{
"@type": "Question",
"name": "La protéogénomique est-elle utilisée en médecine personnalisée ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle permet d'adapter les traitements en fonction du profil protéique du patient."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent être liés à des anomalies protéiques ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes variés comme la fatigue, la douleur ou des troubles neurologiques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles étudiées en protéogénomique ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la protéogénomique aide à comprendre les mécanismes sous-jacents des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Comment les protéines affectent-elles les symptômes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les protéines peuvent influencer des voies biologiques, entraînant divers symptômes cliniques."
}
},
{
"@type": "Question",
"name": "Les symptômes de maladies métaboliques sont-ils liés à la protéogénomique ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des déséquilibres protéiques peuvent contribuer à des symptômes de maladies métaboliques."
}
},
{
"@type": "Question",
"name": "Peut-on prédire des symptômes grâce à la protéogénomique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des modèles prédictifs basés sur des profils protéiques peuvent anticiper certains symptômes."
}
},
{
"@type": "Question",
"name": "La protéogénomique peut-elle aider à la prévention des maladies ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle permet d'identifier des facteurs de risque protéiques pour des interventions précoces."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont identifiés par la protéogénomique ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme des niveaux anormaux de certaines protéines peuvent indiquer un risque accru."
}
},
{
"@type": "Question",
"name": "Comment la protéogénomique influence-t-elle les programmes de dépistage ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet de cibler des populations à risque pour des dépistages plus efficaces."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir des maladies grâce à des interventions protéogénomiques ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des interventions basées sur des profils protéiques peuvent réduire le risque de maladies."
}
},
{
"@type": "Question",
"name": "La nutrition peut-elle être influencée par la protéogénomique ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle aide à adapter les régimes alimentaires en fonction des besoins protéiques individuels."
}
},
{
"@type": "Question",
"name": "La protéogénomique influence-t-elle les traitements ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle permet de développer des thérapies ciblées basées sur le profil protéique des patients."
}
},
{
"@type": "Question",
"name": "Quels types de traitements sont développés grâce à la protéogénomique ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements biologiques, comme les anticorps monoclonaux, sont souvent développés."
}
},
{
"@type": "Question",
"name": "La protéogénomique aide-t-elle à la résistance aux médicaments ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle identifie des mécanismes de résistance, permettant d'ajuster les traitements."
}
},
{
"@type": "Question",
"name": "Les traitements peuvent-ils être personnalisés grâce à la protéogénomique ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des profils protéiques individuels."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont influencés par la protéogénomique ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments anticancéreux et des immunothérapies sont souvent influencés par cette approche."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir en cas d'anomalies protéiques ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des troubles métaboliques ou des maladies dégénératives peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les maladies cardiovasculaires sont-elles liées à la protéogénomique ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des profils protéiques spécifiques peuvent être associés à un risque accru de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Comment la protéogénomique aide-t-elle à comprendre les complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet d'analyser les interactions entre gènes et protéines, révélant des mécanismes de complications."
}
},
{
"@type": "Question",
"name": "Les complications liées à la protéogénomique sont-elles évitables ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par des interventions précoces basées sur des analyses protéiques."
}
},
{
"@type": "Question",
"name": "Peut-on prédire des complications grâce à la protéogénomique ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des modèles prédictifs basés sur des données protéomiques peuvent anticiper des complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque identifiés par la protéogénomique ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'âge, l'hérédité et des niveaux protéiques anormaux sont souvent identifiés."
}
},
{
"@type": "Question",
"name": "La protéogénomique peut-elle identifier des risques environnementaux ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut révéler comment des facteurs environnementaux influencent les profils protéiques."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles les facteurs de risque protéogénomiques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme l'alimentation et l'exercice peuvent modifier les niveaux protéiques."
}
},
{
"@type": "Question",
"name": "Comment la génétique influence-t-elle les facteurs de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "La génétique détermine la production de certaines protéines, influençant ainsi le risque de maladies."
}
},
{
"@type": "Question",
"name": "Peut-on modifier les facteurs de risque grâce à la protéogénomique ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des interventions ciblées peuvent aider à modifier les niveaux protéiques et réduire les risques."
}
}
]
}
]
}
To evaluate the value of combined detection of serum CA125, CA199, and HE4 in the diagnosis of ovarian cancer....
Relevant articles retrieved from PubMed, Elsevier Science, Springer, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases were screened strictly according to inclusion and exclus...
The results of meta-analysis showed that there was a statistical difference in diagnostic specificity analysis of CA125 (OR = 1.91, 95% CI (1.58, 2.32),...
In the clinical assisted diagnosis of ovarian cancer, combined detection of CA125, CA199, and HE4 has the stronger discriminant ability and higher accuracy than single detection of CA125, which can im...
Embryo quality is an important determinant of successful implantation and a resultant live birth. Current clinical approaches for evaluating embryo quality rely on subjective morphology assessments or...
Increase in body mass index (BMI) in early childhood (1-6 years) was found to be a contributing factor for impaired final height in boys with Cystic Fibrosis (CF). Early adrenarche (before age 9 years...
Boys with CF, aged 8-9 years, visiting the CF expertize center Utrecht were included. Since 2018, anthropomorphic, pubertal and endocrine data were collected. Early adrenarche in boys was defined as a...
Thirteen boys (mean age 8.55 ± 0.27 years) were enrolled. The median (IQR) DHEAS-level was 1.3 µmol/L (0.71-2.40). Eight boys (61.5%) had an early rise in DHEAS-levels ≥ 1 µmol/L. Mean increase in BMI...
In this small cohort, 61.5% of boys with CF between 8 and 9 years had an early rise of DHEAS, which was correlated to ΔBMI...
Early childhood caries (ECC) is prevalent worldwide. Oral health promotion effectively utilizes key messages to educate parents/caregivers and the public on how to prevent ECC. Instagram is one of the...
This study used inductive content analysis to categorize, quantify, and interpret pictorial and textual data derived from Instagram posts containing the most commonly used ECC-related hashtags in thei...
A total of 1,071 images and 3,228 comments were analyzed based on 13 hashtags. The most common types of images were those of people (57.5%) and graphics/memes (37.8%). Most people were older children ...
As more people engage with social media, health professionals should consider the potential for Instagram as a tool to promote early childhood oral health and to prevent ECC. Our study shows that many...
Lung cancer continues to be the leading cause of cancer-related mortality worldwide. Early detection and a comprehensive understanding of tumor-immune interactions are crucial for improving patient ou...
The combination of cyclin-dependent kinases 4/6 (CDK4/6) inhibitors and endocrine therapy is the standard treatment for patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced bre...
This study aimed to evaluate the efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in patients with HR+, HER2- early breast cancer. A systematic r...
Eight randomized controlled trials (RCTs) were included in the study. CDK4/6 inhibitors combined with endocrine therapy showed a significant improvement in IDFS (hazard ratio (HR) = 0.81, 95% confiden...
The addition of CDK4/6 inhibitors in HR+/HER2- early breast cancer patients significantly improved IDFS in adjuvant therapy and CCCA in neoadjuvant. However, CDK4/6 inhibitors also showed significant ...
Identifier CRD42024530704....
To compare oncological outcomes in patients with early-stage high-intermediate or high-risk endometrial cancer undergoing surgical staging by laparotomy, conventional laparoscopy, or robot-assisted la...
Patients diagnosed between 2015 and 2021 with stage I-II (International Federation of Gynecology and Obstetrics 2009), high-intermediate or high-risk endometrial cancer who underwent staging surgery, ...
In total 941 patients met the inclusion criteria, of whom 399 (42.4%) underwent staging surgery by laparotomy, 273 (29.0%) by laparoscopy, and 269 (28.6%) by robot-assisted laparoscopy. Baseline chara...
Laparoscopic and robot-assisted laparoscopic staging surgery in women with early-stage high-intermediate or high-risk endometrial cancer are safe alternatives to laparotomic staging surgery....
Childhood, teenage and young adult (CTYA, 0-24 years) cancers are rare and diverse, making timely diagnosis challenging. We aim to explore symptoms and symptom combinations associated with a subsequen...
Using the QResearch Database, we carried out a matched nested case-control study. Associations between pre-specified symptoms encountered in primary care and a subsequent diagnosis of any cancer were ...
3186 cases and 50,576 controls were identified from a cohort of 3,424,771 CTYA. We identified 12 novel associations, of which hemiparesis [OR 90.9 (95%CI 24.7-335.1), PPV = 1.6%], testicular swelling ...
Using the largest cohort to date, we provide novel information on the time-varying predictive utility of symptoms in the diagnosis of CTYA cancers. Our findings will help to raise clinical and public ...
Approximately 20% of patients with colorectal cancer (CRC) are diagnosed with a mucinous subtype of this tumor, have a worse prognosis, and often show resistance to available therapies. Molecules from...
Breast cancer radiotherapy can increase the risks of heart disease, lung cancer and oesophageal cancer. At present, the best dosimetric predictors of these risks are mean doses to the whole heart, lun...
A systematic review and meta-analysis was conducted of planned or delivered mean doses to the whole heart, lungs or oesophagus from UK breast cancer radiotherapy in studies published during 2015-2023....
For whole heart, thirteen studies reported 2893 doses. Average mean doses were higher in left than in right-sided radiotherapy and increased with extent of clinical targets. For left-sided radiotherap...
The typical doses to these organs may be combined with dose-response relationships to estimate radiation risks. Estimated 30-year absolute lung cancer mortality risks from modern UK breast cancer radi...